Cordis and Medinol have announced that the first US commercial cases using the Elunir drug-eluting stent have taken place at New York-Presbyterian Hospital/Columbia University Medical Center in New York and the Piedmont Heart Institute in Atlanta (both USA). The US FDA approved the stent for the treatment of patients with narrowing in their coronary arteries and it is now being distributed to cath labs in the USA by Cordis.
According to a press release, the Elunir stent system is designed to help clinicians easily deliver the new drug-eluting stent in highly complex anatomy and disease and offers a novel metallic spring tip and the narrowest strut width of any stent on the US market.
Martin B Leon (Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center, New York, USA) says: “Our first patient cases with the Elunir stent went perfectly, and we are enthusiastic about the overall performance including the uniform vessel coverage and the delivery system with the metallic spring tip, which is unlike any other product in the market. I have been following Medinol for over 20 years and am excited to see yet another one of the company’s innovative products launch in the US market.”
Cardinal Health and Medinol entered into a long-term distribution agreement that gives Cordis, Cardinal Health’s interventional vascular business, the rights to sell Medinol’s coronary stent portfolio, which now includes the Elunir drug-eluting stent and NIRxcell, a cobalt-chromium bare metal stent, in the USA.
“We are confident that the novel stent and delivery system of the Elunir drug-eluting stent will offer ease of delivery, especially in highly complex cases. Cordis is committed to bringing new technologies, like Elunir, to the market to provide even more treatment options for clinicians and their patients affected by coronary artery disease,” says Luis Davila, vice president of R&D at Cordis.